Prasterone

Overview

Prasterone, also known as dehydroepiandrosterone (DHEA) and sold under the brand name Intrarosa among others, is a medication as well as over-the-counter dietary supplement which is used to correct DHEA deficiency due to adrenal insufficiency or old age, as a component of menopausal hormone therapy, to treat painful sexual intercourse due to vaginal atrophy, and to prepare the cervix for childbirth, among other uses. It is taken by mouth, by application to the skin, in through the vagina, or by injection into muscle.[1][2] WP

Side effects of prasterone in women include symptoms of masculinization like oily skin, acne, increased hair growth, voice changes, and increased sexual desire, headaches, insomnia, and others. The compound is a naturally occurring prohormone of androgens and estrogens and hence is an agonist of the androgen and estrogen receptors, the respective biological targets of androgens like testosterone and estrogens like estradiol. Prasterone also has a variety of activities of its own, including neurosteroid and other activities.[1][2][3] WP

DHEA, the active ingredient of prasterone, was discovered in 1934. An association between DHEA levels and aging was first reported in 1965. The compound started being used as a medication in the late 1970s and as a supplement in the early 1980s. The marketing of prasterone over-the-counter as a supplement is allowed in the United States but is banned in many other countries.[1][2] WP

Drug class

Androgen Anabolic steroid Estrogen Neurosteroid WP

From the Wikipedia article's infobox.

Uses, dosage and effects

Deficiency

DHEA and DHEA sulfate (DHEA-S) are produced by the adrenal glands. In people with adrenal insufficiency such as in Addison's disease, there may be deficiency of DHEA and DHEA-S. In addition, levels of these steroids decrease throughout life and are 70 to 80% lower in the elderly relative to levels in young adults. Prasterone can be used to increase DHEA and DHEA-S levels in adrenal insufficiency and older age. Although there is deficiency of these steroids in such individuals, clinical benefits of supplementation, if any, are uncertain, and there is insufficient evidence at present to support the use of prasterone for such purposes.[4][5] WP

Menopause

Prasterone is sometimes used as an androgen in menopausal hormone therapy. In addition to prasterone itself, a long-lasting ester prodrug of prasterone, prasterone enanthate, is used in combination with estradiol valerate for the treatment of menopausal symptoms under the brand name Gynodian Depot. The current evidence of any benefit of DHEA supplementation to menopausal and postmenopausal women is inconclusive. Whereas prasterone (DHEA) supplementation in postmenopausal women can lead to an increase in E1, E2, testosterone, DHEA, and DHEAS serum levels, and a reduction in SHBG; still, the current evidence regarding the benefits of DHEA supplementation in postmenopausal women is inconclusive—while some studies suggest potential benefits, such as improved well-being, sexual function, and possibly decreased menopausal symptoms, these findings are not universally agreed upon. Moreover, the long-term safety data for DHEA supplementation is lacking, which is a significant concern. This is particularly relevant given that DHEA supplementation can lead to increased estrogenic availability, which could potentially have implications for conditions sensitive to hormonal levels.[6–18] WP

Vaginal atrophy

Prasterone, under the brand name Intrarosa, is approved in the United States in a vaginal insert formulation for the treatment of atrophic vaginitis. The mechanism of action of prasterone for this indication is unknown, though it may involve local metabolism of prasterone into androgens and estrogens.[19][20] WP

Sexual desire

Prasterone has been used orally at a dosage of 10 mg/day to increase sexual desire in women.[21] WP

Childbirth

As the sodium salt of prasterone sulfate (brand names Astenile, Mylis, Teloin), an ester prodrug of prasterone, prasterone is used in Japan as an injection for the treatment of insufficient cervical ripening and cervical dilation during childbirth.[22–30] WP

Available forms

Prasterone was previously marketed as a pharmaceutical medication under the brand name Diandrone in the form of a 10 mg oral tablet in the United Kingdom.[21] WP

Dose-response of hormone levels

At a high dosage of 1,600 mg/day orally for 4 weeks, treatment of postmenopausal women with prasterone has been found to increase serum levels of DHEA by 15-fold, testosterone by 9-fold, DHEA-S, androstenedione, and DHT all by 20-fold, and estrone and estradiol both by 2-fold.[31][32] WP

Although prasterone can reliably increase testosterone levels in women, this isn't similarly the case in men. A high dosage of 1,600 mg/day prasterone in men for 4 weeks was found to increase DHEA and androstenedione levels but did not significantly affect testosterone levels.[33] WP

Dosing

In clinical studies of prasterone supplementation, dosages have ranged from 20 to 1,600 mg per day.[34] WP

In people with adrenal insufficiency, oral dosages of 20 to 50 mg/day prasterone have been found to restore DHEA and DHEA-S levels to physiological levels seen in young healthy adults. Conversely, oral dosages of 100 to 200 mg/day prasterone have been found to result in supraphysiological levels of DHEA and DHEA-S.[34] WP

Micronization of prasterone has been found to significantly increase levels of DHEA-S achieved with oral administration, but to produce no significant change in levels of DHEA or testosterone levels achieved.[35] WP

Anabolic uses

A meta-analysis of intervention studies shows that prasterone supplementation in elderly men can induce a small but significant positive effect on body composition that is strictly dependent on prasterone conversion into its bioactive metabolites such as androgens or estrogens. Evidence is inconclusive regarding the effect of prasterone on strength in the elderly. In middle-aged men, no significant effect of prasterone supplementation on lean body mass, strength, or testosterone levels was found in a randomized placebo-controlled trial.[36][37][38] WP

Risks and side effects

Side effects

Prasterone is produced naturally in the human body, but the long-term effects of its use are largely unknown. In the short term, several studies have noted few adverse effects. In a study by Chang et al., prasterone was administered at a dose of 200 mg/day for 24 weeks with slight androgenic effects noted. Another study used a dose up to 400 mg/day for 8 weeks with few adverse events reported. A longer-term study followed patients dosed with 50 mg of prasterone for 12 months with the number and severity of side effects reported to be small. Another study delivered a dose of 50 mg of prasterone for 10 months with no serious adverse events reported.[39–44] WP

As a hormone precursor, there have been reports of side effects possibly caused by the hormone metabolites of prasterone.[40] WP

It is not known whether prasterone is safe for long-term use. Some researchers believe prasterone supplements might actually raise the risk of breast cancer, prostate cancer, heart disease, diabetes, and stroke. Prasterone may stimulate tumor growth in types of cancer that are sensitive to hormones, such as some types of breast, uterine, and prostate cancer. Prasterone may increase prostate swelling in men with benign prostatic hyperplasia (BPH), an enlarged prostate gland.[39][40] WP

Prasterone is a steroid hormone. High doses may cause aggressiveness, irritability, trouble sleeping, and the growth of body or facial hair on women. It also may stop menstruation and lower the levels of HDL cholesterol, which could raise the risk of heart disease. Other reported side effects include acne, heart rhythm problems, liver problems, hair loss (from the scalp), and oily skin. It may also alter the body's regulation of blood sugar.[39] WP

Prasterone may promote tamoxifen resistance in breast cancer. It may also increase the risk of uterine and prostate cancers due to metabolism into estrogens and androgens, respectively. Patients on hormone replacement therapy may have more estrogen-related side effects when taking prasterone. This supplement may also interfere with other medicines, and potential interactions between it and drugs and herbs are possible.[33][39] WP

Prasterone is possibly unsafe for individuals experiencing pregnancy, breastfeeding, hormone sensitive conditions, liver problems, diabetes, depression or mood disorders, polycystic ovarian syndrome (PCOS), or cholesterol problems.[45] WP

Prasterone has been reported to possess few or no side effects even at very high dosages (e.g., 50 times the recommended over-the-counter supplement dosage). However, it may cause masculinization and other androgenic side effects in women and gynecomastia and other estrogenic side effects in men.[33] WP

Pharmacology

Pharmacokinetics

Oral uptake of prasterone is excellent. Its volume of distribution is 17.0-38.5L (whereas it is 8.5-9.3L for its active metabolite DHEA-S). Prasterone (DHEA) has a biological half-life of 15-38 min (whereas it is 7-22h for DHEA-S). 51-73% of DHEA-S and its metabolites are excreted via the renal route.[46] WP

Prasterone is metabolized into androgens and estrogens in the body, including androstenedione, testosterone, estrone, estradiol, and estriol. The transformation of prasterone into androgens and estrogens is tissue-specific, for instance occurring in the liver, fat, vagina, prostate gland, skin, and hair follicles (as well as other tissues).[3][46][47][48] WP

Metabolism

Prasterone is also reversibly transformed into its active metabolite prasterone sulfate (DHEA-S) by steroid sulfotransferase (specifically SULT1E1 and SULT2A1), which in turn can be converted back into prasterone by steroid sulfatase. Interconversion takes place in both adrenal and peripheral tissues.[3][46][49] WP

It is transformed into androstenedione by 3β-hydroxysteroid dehydrogenase (3β-HSD), and into androstenediol by 17β-hydroxysteroid dehydrogenase (17β-HSD). Then, androstenedione and androstenediol can be converted into testosterone by 17β-HSD and 3β-HSD, respectively. Subsequently, testosterone can be metabolized into dihydrotestosterone by 5α-reductase.[3][47] WP

In addition, androstenedione and testosterone can be converted into estrone and estradiol by aromatase, respectively.[3][47] WP

Research

Cancer

There is no evidence prasterone is of benefit in treating or preventing cancer.[39] WP

Cardiovascular disease

A review in 2003 found the then-extant evidence sufficient to suggest that low serum levels of DHEA-S may be associated with coronary heart disease in men, but insufficient to determine whether prasterone supplementation would have any cardiovascular benefit.[50] WP

Prasterone may enhance G6PD mRNA expression, confounding its inhibitory effects.[51] WP

Lupus

There is some evidence of short-term benefit in those with systemic lupus erythematosus but little evidence of long-term benefit or safety. Prasterone was under development for the treatment of systemic lupus erythematosus in the United States and Europe in the 1990s and 2000s and reached phase III clinical trials and preregistration for this indication, respectively, but ultimately development was not continued past 2010.[1][52][53][54] WP

Memory

Prasterone supplementation has not been found to be useful for memory function in normal middle aged or older adults. It has been studied as a treatment for Alzheimer's disease, but there is no evidence that it is effective or ineffective, so its benefits for that condition are unknown.[55][56] WP

Mood

A few small, short term clinical studies have found that prasterone improves mood but its long-term efficacy and safety, and how it compares to antidepressants, was unknown as of 2015.[57][58] WP

History

History

DHEA was discovered, via isolation from male urine, by Adolf Butenandt and Hans Dannenbaum in 1934, and the compound was isolated from human blood plasma by Migeon and Plager in 1954. DHEA sulfate, the 3β-sulfate ester of DHEA, was isolated from urine in 1944, and was found by Baulieu to be the most abundant steroid hormone in human plasma in 1954. From its discovery in 1934 until 1959, DHEA was referred to by a number of names in the literature, including dehydroandrosterone, transdehydroandrosterone, dehydroisoandrosterone, and androstenolone. The name dehydroepiandrosterone, also known as DHEA, was first proposed by Fieser in 1949, and subsequently became the most commonly used name of the hormone. For decades after its discovery, DHEA was considered to be an inactive compound that served mainly as an intermediate in the production of androgens and estrogens from cholesterol. In 1965, an association between DHEA sulfate levels and aging was reported by De Nee and Vermeulen. Following this, DHEA became of interest to the scientific community, and numerous studies assessing the relationship between DHEA and DHEA sulfate levels and aging were conducted.[1][2] WP

Prasterone, the proposed INN (International Nonproprietary Name) and recommended INN (International Nonproprietary Name) of DHEA and the term used when referring to the compound as a medication, were published in 1970 and 1978, respectively. The combination of 4 mg estradiol valerate and 200 mg prasterone enanthate in an oil solution was introduced for use in menopausal hormone therapy by intramuscular injection under the brand name Gynodian Depot in Europe by 1978. In the early 1980s, prasterone became available and was widely sold over-the-counter as a non-prescription supplement in the United States, primarily as a weight loss aid. It was described as a "miracle drug", with supposed anti-aging, anti-obesity, and anti-cancer benefits. This continued until 1985, when the marketing of prasterone was banned by the Food and Drug Administration (FDA) due to a lack of evidence for health benefits and due to the long-term safety and risks of the compound being unknown at the time. Subsequently, prasterone once again became available over-the-counter as a dietary supplement in the United States following the passage of the Dietary Supplement Health and Education Act of 1994. Conversely, it has remained banned as a supplement in Canada, the United Kingdom, Australia, and New Zealand.[1][2][59–66] WP

In 2001, Genelabs submitted a New Drug Application of prasterone for the treatment of systemic lupus erythematosus (SLE) to the FDA. It had the tentative brand names Anastar, Aslera, and Prestara. However, this application was not approved, and while development of prasterone for SLE in both the United States and Europe continued until up to 2010, the medication was ultimately never approved for the treatment of this condition. In 2016, the FDA approved prasterone in an intravaginal gel formulation for the treatment of painful sexual intercourse due to vulvovaginal atrophy in the United States under the brand name Intrarosa. This was the first prasterone-containing medication to be approved by the FDA in this country.[1][53][54][67][68] WP

Legal status

Generic names

Prasterone is the generic name of DHEA in English and Italian and its International Nonproprietary Name, United States Adopted Name and Italian Common Name, while its generic name is prasteronum in Latin, prastérone in French and its French popular name, and prasteron in German.[24][69][70][71] WP

Marketing

In the United States, prasterone or prasterone sulfate have been advertised, under the names DHEA and DHEA-S, with claims that they may be beneficial for a wide variety of ailments. Prasterone and prasterone sulfate are readily available in the United States, where they are sold as over-the-counter dietary supplements.[72] WP

In 1996, reporter Harry Wessel of the Orlando (Florida) Sentinel wrote about DHEA that "Thousands of people have gotten caught up in the hoopla and are buying the stuff in health food stores, pharmacies and mail-order catalogs" but that "such enthusiasm is viewed as premature by many in the medical field." He noted that "National publications such as Time, Newsweek and USA Today have run articles recently about the hormone, while several major publishers have come out with books touting it." His column was widely syndicated and reprinted in other U.S. newspapers.[73] WP

The product was being "widely marketed to and used by bodybuilders," Dr. Paul Donahue wrote in 2012 for King Features syndicate.[74] WP

Australia

In Australia, a prescription is required to buy prasterone, where it is also comparatively expensive compared to off-the-shelf purchases in US supplement shops. Australian customs classify prasterone as an "anabolic steroid[s] or precursor[s]" and, as such, it is only possible to carry prasterone into the country through customs if one possesses an import permit which may be obtained if one has a valid prescription for the hormone.[75] WP

Canada

In Canada, prasterone is a Controlled Drug listed under Section 23 of Schedule IV of the Controlled Drugs and Substances Act and as such is available by prescription only.[76] WP

United kingdom

Prasterone is listed as an anabolic steroid and is thus a class C controlled drug. WP

United states

Prasterone is legal to sell in the United States as a dietary supplement. It is currently grandfathered in as an "Old Dietary Ingredient" being on sale prior to 1994. Prasterone is specifically exempted from the Anabolic Steroid Control Act of 1990 and 2004.[77] WP

Sports and athletics

Prasterone is banned from use in athletic competition. It is a prohibited substance under the World Anti-Doping Code of the World Anti-Doping Agency, which manages drug testing for Olympics and other sports.[1][2][65][78] WP

• Yulia Efimova, who holds the world record pace for both the 50-meter and 200-meter breaststroke, and won the bronze medal in the 200-meter breaststroke in the 2012 London Olympic Games, tested positive for prasterone in an out-of-competition doping test.[79] WP
• Rashard Lewis, then with the Orlando Magic, tested positive for prasterone and was suspended 10 games before the start of the 2009–10 season.[80] WP
• In 2016 MMA fighter Fabio Maldonado revealed he was taking prasterone during his time with the UFC.[81] WP
• In January 2011, NBA player O. J. Mayo was given a 10-game suspension after testing positive for prasterone. Mayo termed his use of prasterone as "an honest mistake," saying the prasterone was in an over-the-counter supplement and that he was unaware the supplement was banned by the NBA. Mayo was the seventh player to test positive for performance-enhancing drugs since the league began testing in 1999.[82] WP
• Olympic 400-meter champion Lashawn Merritt tested positive for prasterone in 2010 and was banned from the sport for 21 months.[83] WP
• Tennis player Venus Williams had permission from the International Tennis Federation to use DHEA along with hydrocortisone as a treatment for "adrenal insufficiency," but it was revoked in 2016 by the World Anti-Doping Agency, which believed DHEA use would enhance Williams' athletic performance.[84] WP

Chemistry

Formula

C19H28O2 PC

CAS number

53-43-0 PC

Molar mass (g/mol)

288.4 PC

IUPAC name (computed by PubChem)

(3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one PC

SMILES

C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)O)C PC

InChIKey

FMGSKLZLMKYGDP-USOAJAOKSA-N PC

PubChem CID

5881

IUPAC name

(3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta WP

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Cupp MJ, Tracy TS. Dietary Supplements: Toxicology and Clinical Pharmacology. 10 December 2002
2. Journal / agency Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R. Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs. July 2014. doi:10.1007/s40265-014-0259-8 · PMID 25022952
3. Journal / agency Prough RA, Clark BJ, Klinge CM. Novel mechanisms for DHEA action. Journal of Molecular Endocrinology. April 2016. doi:10.1530/JME-16-0013 · PMID 26908835
4. Journal / agency Arlt W. Dehydroepiandrosterone and ageing. Best Practice & Research. Clinical Endocrinology & Metabolism. September 2004. doi:10.1016/j.beem.2004.02.006 · PMID 15261843
5. Journal / agency Alkatib AA, Cosma M, Elamin MB, Erickson D, Swiglo BA, Erwin PJ, Montori VM. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. The Journal of Clinical Endocrinology and Metabolism. October 2009. doi:10.1210/jc.2009-0672 · PMID 19773400
6. Journal / agency Wierman ME, Kiseljak-Vassiliades K. Should Dehydroepiandrosterone be Administered to Women?. The Journal of Clinical Endocrinology and Metabolism. 2022. doi:10.1210/clinem/dgac130 · PMID 35254428 · PMC9113789
7. Journal / agency Benini V, Ruffolo AF, Casiraghi A, Degliuomini RS, Frigerio M, Braga A, Serati M, Torella M, Candiani M, Salvatore S. New Innovations for the Treatment of Vulvovaginal Atrophy: An Up-to-Date Review. Medicina (Kaunas, Lithuania). 2022. doi:10.3390/medicina58060770 · PMID 35744033 · PMC9230595
8. Other Lobo RA. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. 5 June 2007
9. Other Gynodian Depot
10. Other Horsky J, Presl J. Ovarian Function and its Disorders: Diagnosis and Therapy. 6 December 2012
11. Other Platt D. Geriatrics 3: Gynecology · Orthopaedics · Anesthesiology · Surgery · Otorhinolaryngology · Ophthalmology · Dermatology. 6 December 2012
12. Other Campbell S. The Management of the Menopause & Post-Menopausal Years: The Proceedings of the International Symposium held in London 24–26 November 1975 Arranged by the Institute of Obstetrics and Gynaecology, The University of London. 6 December 2012
13. Other Bagatell C, Bremner WJ. Androgens in Health and Disease. 27 May 2003
14. Journal / agency Frigo P, Eppel W, Asseryanis E, Sator M, Golaszewski T, Gruber D, Lang C, Huber J. The effects of hormone substitution in depot form on the uterus in a group of 50 perimenopausal women--a vaginosonographic study. Maturitas. April 1995. doi:10.1016/0378-5122(94)00893-c · PMID 7616871
15. Journal / agency Salvatore S, Benini V, Ruffolo AF, Degliuomini RS, Redaelli A, Casiraghi A, Candiani M. Current challenges in the pharmacological management of genitourinary syndrome of menopause. Expert Opinion on Pharmacotherapy. 2023. doi:10.1080/14656566.2022.2152326 · PMID 36444726
16. Journal / agency Pan M, Zhou J, Pan X, Wang J, Qi Q, Wang L. Drugs for the treatment of postmenopausal symptoms: Hormonal and non-hormonal therapy. Life Sciences. 2023. doi:10.1016/j.lfs.2022.121255 · PMID 36470539
17. Journal / agency Casiano Evans, Elizabeth A.; Hobson, Deslyn T. G.; Aschkenazi, Sarit O.; Alas, Alexandriah N.; Balgobin, Sunil; Balk, Ethan M.; Dieter, Alexis A.; Kanter, Gregory; Orejuela, Francisco J.; Sanses, Tatiana V. D.; Rahn, David D. Nonestrogen Therapies for Treatment of Genitourinary Syndrome of Menopause: A Systematic Review. Obstetrics and Gynecology. 2023. doi:10.1097/AOG.0000000000005288 · PMID 37543737
18. Journal / agency Marina L, Sojat AS, Maseroli E, Spaggiari G, Pandurevic S, Santi D. Hormonal profile of menopausal women receiving androgen replacement therapy: a meta-analysis. J Endocrinol Invest. June 2020. doi:10.1007/s40618-020-01192-x · PMID 32016915
19. Journal / agency Prasterone vaginal - Bayer/Endoceutics
20. Journal / agency NTRAROSA (prasterone) Vaginal Inserts, ENDOCEUTICS INC Prescribing Information. 17 November 2016
21. Other Brotherton J. Sex Hormone Pharmacology. 1976
22. Other Prasterone Monograph for Professionals
23. Journal / agency Prasterone vaginal - Kanebo
24. Other Elks J. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014
25. Other Blunt JW, Munro MH. Dictionary of Marine Natural Products with CD-ROM. 19 September 2007
26. Other Kleemann A, Engel J, Kutscher B, Reichert D. Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. 14 May 2014
27. Other Negwer M, Scharnow HG. Organic-chemical drugs and their synonyms: (an international survey). 2001
28. Journal / agency Jianqiu Y. Clinical Application of Prasterone Sodium Sulfate. Chinese Journal of New Drugs. 1992
29. Journal / agency Sakaguchi M, Sakai T, Adachi Y, Kawashima T, Awata N. The biological fate of sodium prasterone sulfate after vaginal administration. I. Absorption and excretion in rats. Journal of Pharmacobio-Dynamics. February 1992. doi:10.1248/bpb1978.15.67 · PMID 1403604
30. Journal / agency Sakai T, Sakaguchi M, Adachi Y, Kawashima T, Awata N. The Biological Fate of Sodium Prasterone Sulfate after Vaginal Administration II: Distribution after Single and Multiple Administration to Pregnant Rats. 薬物動態. 1992. doi:10.2133/dmpk.7.87
31. Journal / agency Schwartz AG, Pashko LL. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Research Reviews. April 2004. doi:10.1016/j.arr.2003.05.001 · PMID 15177053
32. Journal / agency Mortola JF, Yen SS. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. The Journal of Clinical Endocrinology and Metabolism. September 1990. doi:10.1210/jcem-71-3-696 · PMID 2144295
33. Other McKeag D, Moeller JL. ACSM's Primary Care Sports Medicine. 2007
34. Other Alesci S, Manoli I, Blackman MR. Encyclopedia of Dietary Supplements. 29 December 2004
35. Journal / agency Casson PR, Straughn AB, Umstot ES, Abraham GE, Carson SA, Buster JE. Delivery of dehydroepiandrosterone to premenopausal women: effects of micronization and nonoral administration. American Journal of Obstetrics and Gynecology. February 1996. doi:10.1016/S0002-9378(96)70444-1 · PMID 8623801
36. Journal / agency Corona G, Rastrelli G, Giagulli VA, Sila A, Sforza A, Forti G, Mannucci E, Maggi M. Dehydroepiandrosterone supplementation in elderly men: a meta-analysis study of placebo-controlled trials. The Journal of Clinical Endocrinology and Metabolism. September 2013. doi:10.1210/jc.2013-1358 · PMID 23824417
37. Journal / agency Baker WL, Karan S, Kenny AM. Effect of dehydroepiandrosterone on muscle strength and physical function in older adults: a systematic review. Journal of the American Geriatrics Society. June 2011. doi:10.1111/j.1532-5415.2011.03410.x · PMID 21649617
38. Journal / agency Wallace MB, Lim J, Cutler A, Bucci L. Effects of dehydroepiandrosterone vs androstenedione supplementation in men. Medicine and Science in Sports and Exercise. December 1999. doi:10.1097/00005768-199912000-00014 · PMID 10613429
39. Other American Cancer Society Complete Guide to Complementary and Alternative Cancer Therapies. 2009
40. Journal / agency Tang J, Chen LR, Chen KH. The Utilization of Dehydroepiandrosterone as a Sexual Hormone Precursor in Premenopausal and Postmenopausal Women: An Overview. Pharmaceuticals. December 2021. doi:10.3390/ph15010046 · PMID 35056103 · PMC8781653
41. Journal / agency Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism. November 2002. doi:10.1002/art.10615 · PMID 12428233
42. Journal / agency Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ, Ferrando SJ. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. The American Journal of Psychiatry. January 2006. doi:10.1176/appi.ajp.163.1.59 · PMID 16390890
43. Journal / agency Brooke AM, Kalingag LA, Miraki-Moud F, Camacho-Hübner C, Maher KT, Walker DM, Hinson JP, Monson JP. Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement. The Journal of Clinical Endocrinology and Metabolism. October 2006. doi:10.1210/jc.2006-0316 · PMID 16849414
44. Journal / agency Villareal DT, Holloszy JO. DHEA enhances effects of weight training on muscle mass and strength in elderly women and men. American Journal of Physiology. Endocrinology and Metabolism. November 2006. doi:10.1152/ajpendo.00100.2006 · PMID 16787962
45. Other DHEA: Side effects and safety
46. Journal / agency Pepping J. DHEA: dehydroepiandrosterone. American Journal of Health-System Pharmacy. November 2000. doi:10.1093/ajhp/57.22.2048 · PMID 11098305
47. Other Burtis CA, Ashwood ER,, Bruns DE. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics - E-Book. 14 October 2012
48. Journal / agency Labrie F, Martel C, Bélanger A, Pelletier G. Androgens in women are essentially made from DHEA in each peripheral tissue according to intracrinology. The Journal of Steroid Biochemistry and Molecular Biology. April 2017. doi:10.1016/j.jsbmb.2016.12.007 · PMID 28153489
49. Journal / agency Mueller JW, Gilligan LC, Idkowiak J, Arlt W, Foster PA. The Regulation of Steroid Action by Sulfation and Desulfation. Endocrine Reviews. October 2015. doi:10.1210/er.2015-1036 · PMID 26213785 · PMC4591525
50. Journal / agency Thijs L, Fagard R, Forette F, Nawrot T, Staessen JA. Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases? A review of prospective and retrospective studies. Acta Cardiologica. October 2003. doi:10.2143/AC.58.5.2005304 · PMID 14609305
51. Journal / agency Hecker PA, Leopold JA, Gupte SA, Recchia FA, Stanley WC. Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease. American Journal of Physiology. Heart and Circulatory Physiology. February 2013. doi:10.1152/ajpheart.00721.2012 · PMID 23241320 · PMC3566485
52. Journal / agency Crosbie D, Black C, McIntyre L, Royle PL, Thomas S. Dehydroepiandrosterone for systemic lupus erythematosus. The Cochrane Database of Systematic Reviews. October 2007. doi:10.1002/14651858.CD005114.pub2 · PMID 17943841 · PMC8864970
53. Other Blau S, Schultz D. Living With Lupus: The Complete Guide, 2nd Edition. 5 March 2009
54. Journal / agency Prasterone - Genelabs
55. Journal / agency Evans JM, Malouf R, Huppert F, van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people. The Cochrane Database of Systematic Reviews. October 2006. doi:10.1002/14651858.CD006221 · PMID 17054283 · PMC8988513
56. Journal / agency Fuller SJ, Tan RS, Martins RN. Androgens in the etiology of Alzheimer's disease in aging men and possible therapeutic interventions. Journal of Alzheimer's Disease. September 2007. doi:10.3233/JAD-2007-12202 · PMID 17917157
57. Journal / agency Pluchino N, Drakopoulos P, Bianchi-Demicheli F, Wenger JM, Petignat P, Genazzani AR. Neurobiology of DHEA and effects on sexuality, mood and cognition. The Journal of Steroid Biochemistry and Molecular Biology. January 2015. doi:10.1016/j.jsbmb.2014.04.012 · PMID 24892797
58. Journal / agency Maric NP, Adzic M. Pharmacological modulation of HPA axis in depression - new avenues for potential therapeutic benefits. Psychiatria Danubina. September 2013. PMID 24048401
59. Journal / agency International Nonproprietary Names for Pharmaceutical Substances. WHO Chronicle. 1970. PMID 5439245
60. Journal / agency International Nonproprietary Names for Pharmaceutical Substances. WHO Chronicle
61. Journal / agency Hoyme U, Baumueller A, Madsen PO. The influence of pH on antimicrobial substances in canine vaginal and urethral secretions. Urological Research. 1978. doi:10.1007/bf00257080 · PMID 25506
62. Journal / agency Kopera H, Dhont M, Dienstl F, Gambrell RD, Gordan GS, Heidenreich J, Lachnit-Fixon U, Lauritzen C, Lebech PE, Sitruk-Ware RL, Utian WH. Female and Male Climacteric. 1979. doi:10.1007/978-94-011-9720-5_6
63. Journal / agency Mattson LA, Cullberg G, Tangkeo P, Zador G, Samsioe G. Administration of dehydroepiandrosterone enanthate to oophorectomized women--effects on sex hormones and lipid metabolism. Maturitas. December 1980. doi:10.1016/0378-5122(80)90032-8 · PMID 6453267
64. Other Muller. European Drug Index: European Drug Registrations, Fourth Edition. 19 June 1998
65. Other Randolph Jr CW, James G. From Hormone Hell to Hormone Well: Straight Talk Women (and Men) Need to Know to Save Their Sanity, Health, and—Quite Possibly—Their Lives. 1 January 2010
66. Other Dunford M, Doyle JA. Nutrition for Sport and Exercise. 7 February 2014
67. Journal / agency Voelker R. Relief for Painful Intercourse. JAMA. January 2017. doi:10.1001/jama.2016.19077 · PMID 28030684
68. Journal / agency Prasterone (Intrarosa) for Dyspareunia. JAMA. October 2017. doi:10.1001/jama.2017.14981 · PMID 29067420
69. Other Morton IK, Hall JM. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. 6 December 2012
70. Other Prasterone
71. Journal / agency Prasterone
72. Journal / agency Calfee R, Fadale P. Popular ergogenic drugs and supplements in young athletes. Pediatrics. March 2006. doi:10.1542/peds.2005-1429 · PMID 16510635
73. Other Proponents Say DHEA Blunts Effects of Aging. 1 October 1996
74. Other DHEA Supplement a Help or Harm. 18 March 2012
75. Other Personal Importation Scheme
76. Other DHEA listing in the Ingredient Database. 26 July 2004
77. Other Drug Scheduling Actions – 2005
78. Other World Anti-Doping Agency
79. Other Russian Olympic Medal-Winning Swimmer Efimova Fails Doping Test – Report. 17 January 2014
80. Other Tillery R. Memphis Grizzlies' O. J. Mayo suspended 10 games for violating NBA anti-drug program
81. Other Rezende L. Fabio Maldonado plans to use DHEA for Fedor match, admits use in UFC. 28 April 2016
82. Other Memphis Grizzlies' O. J. Mayo gets 10-game drug suspension. 27 January 2011
83. Other US 400m star LaShawn Merritt fails drug test. 22 April 2010
84. Other Ruiz RR, Rothenberg B. Doping. 22 September 2016

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.